Medicenna Therapeutics (TSE:MDNA) Rating Reiterated by Maxim Group

Maxim Group restated their buy rating on shares of Medicenna Therapeutics (TSE:MDNA) in a research report sent to investors on Tuesday morning, TipRanks reports. They currently have a C$9.00 price target on the stock.

MDNA stock traded down C$0.07 during trading hours on Tuesday, hitting C$3.18. The company’s stock had a trading volume of 13,812 shares, compared to its average volume of 87,850. The company has a quick ratio of 7.43, a current ratio of 7.51 and a debt-to-equity ratio of 0.07. The company has a market capitalization of C$170.90 million and a PE ratio of -7.61. Medicenna Therapeutics has a 12 month low of C$2.35 and a 12 month high of C$7.02. The stock has a 50 day moving average price of C$3.05 and a two-hundred day moving average price of C$4.06.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors.

Further Reading: Average Daily Trade Volume Explained

Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.